If you have been reading about secondary drying and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-17. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized products are typically hygroscopic and require protection from moisture during storage. Manufacturers seal them in glass vials, often under vacuum or an inert gas such as nitrogen. The container closure system, including the stopper and crimp seal, must prevent water vapor ingress. Storage temperature varies from controlled room temperature to refrigerated or frozen conditions, depending on the formulation. Humidity-controlled environments are essential because even brief exposure to ambient air can degrade the product.
Stability of a lyophilized product depends on its glass transition temperature, the temperature at which the amorphous cake transitions from a glassy to a rubbery state. Storage below this temperature minimizes molecular mobility and slows chemical degradation. If the storage temperature exceeds the glass transition temperature, the cake may collapse, shrink, or become sticky. Accelerated stability studies at elevated temperatures and humidity help predict shelf life, but they do not always reflect real-time behavior. Residual moisture content also plays a critical role in long-term stability.
The process usually has three stages: freezing, primary drying, and secondary drying. Freezing sets the ice crystal structure and can determine pore size in the final cake. Primary drying removes free ice by sublimation at low pressure and low shelf temperature. Secondary drying removes bound water by raising the shelf temperature, although some water may remain as part of the solid. Cycle parameters depend on formulation, fill volume, vial type, and equipment performance.
The physical chemistry of freezing influences whether a formulation forms an amorphous glass or a crystalline solid. Amorphous systems can collapse if product temperature rises above the glass transition temperature of the freeze concentrate. Crystalline systems may show eutectic melting, where ice and solute melt together at a fixed temperature. Formulators add bulking agents, lyoprotectants, and buffers to preserve structure and biological activity. The optimum cycle keeps product temperature below critical thresholds during primary drying while allowing efficient sublimation.
Lyophilization is a dehydration process that removes water from a frozen material by sublimation under low pressure. The material is first frozen so that water becomes ice; then the surrounding pressure is lowered below the vapor pressure of ice. Heat is applied gently so ice changes directly to vapor without passing through a bulk liquid phase. The vapor is collected on a cold condenser, leaving a dry porous matrix. This process differs from simple evaporation because the material remains frozen during the main drying stage.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white porous cake | Color depends on formulation. |
| Typical storage temperature | 2–8 °C | Refrigerated for many biologics. |
| Residual moisture | <1% to 3% | Low moisture improves stability. |
| Container | Sealed glass vial | Often with rubber stopper and aluminum crimp. |
| Reconstitution time | Seconds to minutes | Varies with cake density and diluent. |
After lyophilization, a product's quality depends on residual moisture, cake appearance, and reconstitution time. Residual moisture is often measured by Karl Fischer titration or thermogravimetric analysis. A low moisture content can slow chemical degradation, but overly dry cakes may be brittle or slow to dissolve. Stability studies track these attributes over months under defined temperature and humidity conditions. Batch records link these measurements to specific process runs and help identify trends before a product fails specification.
Storage conditions for dried products usually aim to exclude moisture and oxygen. Vials are sealed under vacuum or with an inert gas, and stoppers must maintain a barrier during transport. Temperature recommendations vary; some materials remain stable at room temperature, while others need refrigeration or frozen storage. Humidity control is critical because dried cakes can absorb water rapidly once a container is opened. Desiccant packs and moisture-barrier bags add further protection during shipping.
Quality control also examines cake structure, color, and reconstitution behavior. A collapsed or shrunken cake can indicate a thermal excursion during drying. Analytical methods such as X-ray diffraction, differential scanning calorimetry, and near-infrared spectroscopy can detect crystallinity or moisture distribution. Regulatory expectations focus on validated assays and lot-to-lot consistency. Questions remain about how well accelerated stability tests predict long-term behavior for every formulation. Visual inspection remains common but is subjective without trained reviewers and reference images.
Freezing is the first stage and sets the ice structure that later becomes the pore network. The formulation is cooled below its freezing point, often with a controlled ramp, and solutes concentrate as ice forms. Primary drying then lowers chamber pressure and supplies heat to sublime the ice. The product temperature must stay below its collapse or eutectic temperature to prevent structural loss. Secondary drying raises the temperature modestly to remove bound water and achieve a low residual moisture.
A freeze-dryer consists of a vacuum chamber, temperature-controlled shelves, a condenser, and a vacuum pump. Vials, ampoules, or bulk trays hold the product during the cycle. The condenser traps water vapor as ice at a temperature lower than the product. Cycle development balances shelf temperature, chamber pressure, and time. Scale-up can be difficult because heat and mass transfer change with equipment size, so process analytical tools and conservative validation are often used.
Lyophilization is a dehydration technique in which a product is frozen and the solvent is removed under reduced pressure. The low pressure allows ice to sublimate directly into vapor without passing through a bulk liquid phase. This differs from conventional drying, where heat drives evaporation and can damage heat-sensitive structures. The process is used for biological materials, pharmaceutical formulations, and some foods. Its main advantage is preservation of porous structure and rapid reconstitution.
After drying, a lyophilized product is usually sealed under vacuum or an inert gas to limit moisture uptake. Residual water content is measured because small changes can alter chemical stability and cake appearance. Storage temperature depends on the material; many biological products are kept at 2–8 °C, while some require −20 °C or colder. Exposure to ambient humidity during handling can cause the porous solid to absorb water and collapse. Container closures and stoppers are therefore selected for low moisture transmission and compatibility.
Quality control for lyophilized materials includes visual inspection of the cake, measurement of residual moisture, and tests for reconstitution time. An acceptable cake is typically uniform and may be slightly porous; shrinkage, meltback, or cracks can indicate process deviations. Analytical methods such as Karl Fischer titration, thermogravimetric analysis, and near-infrared spectroscopy quantify water content. Reconstitution time is recorded because a very slow or incomplete dissolution can signal collapse or aggregation. Stability studies compare samples stored under defined temperature and humidity conditions over months or years.
Regulatory expectations for lyophilized products focus on consistent manufacture and documented stability. Batches are often monitored for moisture, appearance, potency, and sterility where applicable. Process parameters such as shelf temperature, chamber pressure, and drying time are recorded and controlled within validated ranges. Open questions remain about how best to predict long-term stability from short accelerated studies, especially for complex biologics. Variations in freezing rate and ice crystal size can produce differences that are not always visible but may affect performance.
Formulation composition influences whether freeze-drying produces an intact cake or a collapsed mass. Excipients such as sugars and polymers can raise the collapse temperature and provide bulk during drying. The critical temperature for primary drying is often the collapse temperature or the glass transition temperature of the maximally concentrated phase. If the product temperature exceeds this threshold, the frozen matrix may soften and lose structure. Established practice therefore links shelf temperature and chamber pressure to the formulation's thermal properties.
The physics of freeze-drying couples heat transfer, mass transfer, and phase change. Heat supplied through the shelf must reach the sublimation front without melting the ice or degrading the product. Water vapor then travels through the already dried layer and leaves the chamber, where low pressure and cold traps keep it from returning. The dried layer acts as a resistance to vapor flow, so drying rate changes as the front recedes. Open questions remain about how pore structure and formulation heterogeneity affect drying uniformity at larger scales.
Lyophilization removes water from a frozen material by sublimation under reduced pressure. The process begins with freezing, which converts liquid water into ice and concentrates dissolved solids. Primary drying then lowers chamber pressure so ice changes directly into vapor without passing through a liquid phase. Secondary drying raises the shelf temperature to remove bound water that remains after ice sublimation. The result is a dry, porous structure that can be reconstituted later.
Distribution of products takes place through a marketing channel, also known as a distribution channel. A marketing channel is the people, organizations, and activities necessary to transfer the ownership of goods from the point of production to the point of consumption. It is the way products get to the end-user, the consumer. This is mostly accomplished through merchant retailers or wholesalers or, in the international context, by importers. In certain specialist markets, agents or brokers may become involved in the marketing channel: for example in the insurance sector, the European Union has noted that "insurance and reinsurance intermediaries play a central role in the distribution of insurance and reinsurance products" . The EU introduced the Insurance Distribution Directive in 2016 to enhance a level of harmonisation in this market across EU member states. Typical intermediaries involved in distribution include:
Street purity of 2C-B, when tested, has been found to be relatively high. Researchers in Spain found that 2C-B samples in the country doubled between 2006 and 2009, switched from primarily powder form to tablets, and exhibited "low falsification rates". An analysis of street samples in the Netherlands found impurities "in small percentages"; only one of the impurities, the N-acetyl derivative of 2C-B, could be identified, and comprised 1.3% of the sample. The authors suggested that this compound was a by-product of 2C-B synthesis. In 2011, street prices in the United States ranged between $10 and $30 per tablet when purchased in small quantities. Larger retail purchases cost between $200 and $500 per gram. Wholesale purchases of 2C-B would lower the price ($100 to $300 per gram in 2001, $30 to $100 on the darknet in 2020).
=== Not marketed === ACT-335827 – selective OX1 antagonist Almorexant (ACT-078573) – dual OX1 and OX2 antagonist – half-life 13–19 hours – development of the drug was abandoned in January 2011 EMPA – selective OX2 antagonist Filorexant (MK-6096) – dual OX1 and OX2 antagonist – half-life 3–6 hours – development was discontinued in 2015 GSK-649868 (SB-649868) – dual OX1 and OX2 antagonist – was in development for potential use in sleep disorders JNJ-10397049 – selective OX2 antagonist RTIOX-276 – selective OX1 antagonist SB-334867 – first non-peptide selective OX1 antagonist – has been shown to produce sedative and anorectic effects in animals SB-408124 – selective OX1 antagonist TCS-OX2-29 – first non-peptide selective OX2 antagonist
A more complex signal transduction pathway is the MAPK/ERK pathway, which involves changes of protein–protein interactions inside the cell, induced by an external signal. Many growth factors bind to receptors at the cell surface and stimulate cells to progress through the cell cycle and divide. Several of these receptors are kinases that start to phosphorylate themselves and other proteins when binding to a ligand. This phosphorylation can generate a binding site for a different protein and thus induce protein–protein interaction. In this case, the ligand (called epidermal growth factor, or EGF) binds to the receptor (called EGFR). This activates the receptor to phosphorylate itself. The phosphorylated receptor binds to an adaptor protein (GRB2), which couples the signal to further downstream signaling processes. For example, one of the signal transduction pathways that are activated is called the mitogen-activated protein kinase (MAPK) pathway. The signal transduction component labeled as "MAPK" in the pathway was originally called "ERK," so the pathway is called the MAPK/ERK pathway. The MAPK protein is an enzyme, a protein kinase that can attach phosphate to target proteins such as the transcription factor MYC and, thus, alter gene transcription and, ultimately, cell cycle progression. Many cellular proteins are activated downstream of the growth factor receptors (such as EGFR) that initiate this signal transduction pathway. Some signaling transduction pathways respond differently, depending on the amount of signaling received by the cell.
Sources: en.wikipedia.org
== Synthesis == Routes to isoleucine are numerous. One common multistep procedure starts from 2-bromobutane and diethylmalonate. Synthetic isoleucine was first reported in 1905 by French chemists Bouveault and Locquin.
The acceptor stem is a 7- to 9-base pair (bp) stem made by the base pairing of the 5′-terminal nucleotide with the 3′-terminal nucleotide (which contains the CCA tail used to attach the amino acid). The acceptor stem may contain non-Watson-Crick base pairs. The CCA tail is a cytosine-cytosine-adenine sequence at the 3′ end of the tRNA molecule. The amino acid loaded onto the tRNA by aminoacyl tRNA synthetases, to form aminoacyl-tRNA, is covalently bonded to the 3′-hydroxyl group on the CCA tail. This sequence is important for the recognition of tRNA by enzymes and critical in translation. In prokaryotes, the CCA sequence is transcribed in some tRNA sequences. In most prokaryotic tRNAs and eukaryotic tRNAs, the CCA sequence is added during processing and therefore does not appear in the tRNA gene. The D loop is a 4- to 6-bp stem ending in a loop that often contains dihydrouridine. The anticodon loop is a 5-bp stem whose loop contains the anticodon. The TΨC loop is named so because of the characteristic presence of the unusual base Ψ in the loop, where Ψ is pseudouridine, a modified uridine. The modified base is often found within the sequence 5'-TΨCGA-3', with the T (ribothymidine, m5U) and A forming a base pair. The variable loop or V loop sits between the anticodon loop and the ΨU loop and, as its name implies, varies in size from 3 to 21 bases. In some tRNAs, the "loop" is long enough to form a rigid stem, the variable arm. tRNA with a V loop more than 10 bases long is classified as "class II" and the rest is called "class I".
He'd say, 'Hey, I did this. Not you.'" Starr still blamed himself for the death of Staley, and had kept the story a secret until his appearance on Celebrity Rehab. During this same interview, Staley's mother recalled that he had attempted rehab fourteen times, although it is not clear whether any of these attempts were during his reclusive years. Starr was found dead on March 8, 2011, as a result of a prescription drug overdose.
Sources: en.wikipedia.org
=== Lucinda Young === Lucinda Young (Ruby Bentall) is a VP on Pierpoint's Investment Banking Division (IBD), overseeing Gus and Hari. She tacitly encourages Hari to overwork during his first week on the job; after Hari dies of a heart attack, Lucinda feels guilty, and worries whether she will be held culpable for Hari's death, telling Gus to vouch for her with HR. Lucinda is briefly seen in series 2 meeting with executives from healthcare startup Rican, for whom Pierpoint is helping engineer a major trade.
Chavibetol is an organic chemical compound of the phenylpropanoid class. It is one of the primary constituents of the essential oil from the leaves of the betel plant (Piper betel) and catatia. It is an aromatic compound with a spicy odor.
== Manufacturing == Due to speed of light constraints on communication, manufacturing in space at a distant point of resource acquisition will either require completely autonomous robotics to perform the labor, or a human crew with all the accompanying habitat and safety requirements. If the plant is built in orbit around the Earth, or near a crewed space habitat, however, telerobotic devices can be used for certain tasks that require human intelligence and flexibility. Solar power provides a readily available power source for thermal processing. Even with heat alone, simple thermally-fused materials can be used for basic construction of stable structures. Bulk soil from the Moon or asteroids has a very low water content, and when melted to form glassy materials is very durable. These simple, glassy solids can be used for the assembly of habitats on the surface of the Moon or elsewhere. The solar energy can be concentrated in the manufacturing area using an array of steerable mirrors. The availability and favorable physical properties of metals will make them a major component of space manufacturing. Most of the metal handling techniques used on Earth can also be adopted for space manufacturing. A few of these techniques will need significant modifications due to the microgravity environment. The production of hardened steel in space will introduce some new factors. Carbon only appears in small proportions in lunar surface materials and will need to be delivered from elsewhere. Waste materials carried by humans from the Earth is one possible source, as are comets.
42 BC to at least early 5th century, Mark Antony (emblem: capricorn) Legio V Macedonica (Macedonian): 43 BC – AD 637, Octavian (emblem: bull) Legio V Alaudae (Larks): 52 BC – AD 70 or 86 (destroyed either during the Batavian rebellion or by the Dacians in first Battle of Tapae), Julius Caesar (emblem: elephant) Legio VI Ferrata (Ironclad): 52 BC – after AD 250, Julius Caesar (emblem: bull, she-wolf and Romulus and Remus); twin legion of Legio VI Victrix Legio VI Victrix (Victorious): 41 BC – after AD 402, Octavian (emblem: bull) Legio VII Claudia Pia Fidelis (loyal and faithful to Claudius): before 58 BC – 44 BC, Julius Caesar; disbanded and re-formed by Octavian Legio VIII Augusta: 59 BC – 46 BC, Julius Caesar, originally named Gallica, disbanded and re-enlisted by Octavian as Legio VIII Augusta, 44 BC – AD 420 Legio IX Hispana (Hispanian): before 58 BC – AD 120-161 Legio X Equestris (Equestrian): before 58 BC – 45 BC, Julius Caesar's personal legion, later renamed as Legio X Gemina Legio X Fretensis (of the sea strait): levied by Octavian in 41/40 BC, recorded to have existed at least until the 410s Legio XI Claudia: 58 BC – 45 BC, Julius Caesar (emblem: Neptune), disbanded, reconstituted by Octavian Legio XII Fulminata (Thunderbolt): 57 BC – AD 45, Julius Caesar, first reconstituted by Lepidus in 43 BC, named by Mark Antony as Legio XII Antiqua (Ancient) Legio XIII Gemina (Twin): 57 BC – 45 BC: Julius Caesar, later (41 BC) reconstituted by Octavian. The legion that crossed the Rubicon with Caesar on his assault on Rome.
Sources: en.wikipedia.org
Lyophilized products should be stored in airtight containers, protected from moisture and light, at the temperature specified by the manufacturer. Many require refrigeration at 2–8 °C, while some need frozen storage. Always check the product label for specific conditions.
Moisture can cause the porous cake to collapse, increase molecular mobility, and accelerate chemical degradation. It may also promote microbial growth if the product lacks preservatives. Proper sealing and handling are essential to maintain stability.
Some formulations contain labile biological molecules that degrade even in the dry state at higher temperatures. Others have a low glass transition temperature, meaning the cake can soften or collapse at room temperature. Cold storage reduces molecular motion and slows degradation.
The main change is sublimation, in which ice becomes water vapor without melting into liquid water. This occurs when the chamber pressure is held below the vapor pressure of ice while mild heat is supplied. The result is a dry, porous solid that retains much of its original shape.